Jin‐Ji Yang

882 total citations
83 papers, 574 citations indexed

About

Jin‐Ji Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jin‐Ji Yang has authored 83 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pulmonary and Respiratory Medicine, 55 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Jin‐Ji Yang's work include Lung Cancer Treatments and Mutations (75 papers), Colorectal Cancer Treatments and Studies (25 papers) and Lung Cancer Diagnosis and Treatment (25 papers). Jin‐Ji Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (75 papers), Colorectal Cancer Treatments and Studies (25 papers) and Lung Cancer Diagnosis and Treatment (25 papers). Jin‐Ji Yang collaborates with scholars based in China, United States and South Korea. Jin‐Ji Yang's co-authors include Yi‐Long Wu, Qing Zhou, Wen‐Zhao Zhong, Xue‐Ning Yang, Chong‐Rui Xu, Hong‐Hong Yan, Xu‐Chao Zhang, Hua‐Jun Chen, Hai‐Yan Tu and Christian Manegold and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Jin‐Ji Yang

73 papers receiving 570 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jin‐Ji Yang China 13 458 316 138 120 44 83 574
Karl Kölbeck Sweden 11 598 1.3× 483 1.5× 155 1.1× 97 0.8× 28 0.6× 23 736
R. Lamy France 11 425 0.9× 500 1.6× 124 0.9× 142 1.2× 54 1.2× 32 633
H. Doubre France 12 524 1.1× 372 1.2× 113 0.8× 81 0.7× 62 1.4× 33 629
Rinat Galiulin United States 6 388 0.8× 370 1.2× 135 1.0× 110 0.9× 39 0.9× 7 556
N. B. Leighl United States 11 568 1.2× 498 1.6× 206 1.5× 128 1.1× 67 1.5× 32 758
William Berry United States 8 252 0.6× 226 0.7× 297 2.2× 164 1.4× 39 0.9× 16 675
Ofer Rotem Israel 11 312 0.7× 379 1.2× 113 0.8× 99 0.8× 84 1.9× 30 516
Carina Hillenbach Switzerland 7 319 0.7× 383 1.2× 111 0.8× 65 0.5× 13 0.3× 11 630
C. Decroisette France 11 524 1.1× 493 1.6× 130 0.9× 112 0.9× 62 1.4× 50 706
Sook Jung Jo South Korea 6 724 1.6× 692 2.2× 171 1.2× 112 0.9× 86 2.0× 8 865

Countries citing papers authored by Jin‐Ji Yang

Since Specialization
Citations

This map shows the geographic impact of Jin‐Ji Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin‐Ji Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin‐Ji Yang more than expected).

Fields of papers citing papers by Jin‐Ji Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin‐Ji Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin‐Ji Yang. The network helps show where Jin‐Ji Yang may publish in the future.

Co-authorship network of co-authors of Jin‐Ji Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Jin‐Ji Yang. A scholar is included among the top collaborators of Jin‐Ji Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin‐Ji Yang. Jin‐Ji Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Song, Erwei, Yue Yin, Jiuda Zhao, et al.. (2025). LBA25 Culmerciclib plus fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer: A phase III trial (CULMINATE-2). Annals of Oncology. 36. S1569–S1570. 1 indexed citations
2.
3.
Huang, Jie, et al.. (2024). Mixed response to the first‐line treatment of KRAS G12C inhibitor, sotorasib, in non‐small cell lung cancer: A brief report. SHILAP Revista de lepidopterología. 12(6). e8866–e8866. 1 indexed citations
4.
Zhou, Caicun, You Lu, Sang‐We Kim, et al.. (2024). Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study. JTO Clinical and Research Reports. 5(9). 100700–100700. 2 indexed citations
5.
Zhou, Caicun, Jingbo Chen, Long Wang, et al.. (2024). PL02.04 Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2. Journal of Thoracic Oncology. 19(10). S1–S1. 15 indexed citations
6.
Xiao, Fa-Man, Yuqing Chen, Yufa Li, et al.. (2023). Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement. Cancer Treatment and Research Communications. 35. 100707–100707.
7.
Cui, Jiuwei, Qing Zhou, Shun Lü, et al.. (2021). The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options. Translational Lung Cancer Research. 10(8). 3594–3607. 2 indexed citations
8.
Wu, Yi‐Long, Qi Zhou, Hsi‐Feng Tu, et al.. (2018). P1.01-97 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC. Journal of Thoracic Oncology. 13(10). S500–S501. 1 indexed citations
9.
Zhong, Wen‐Zhao, Yi‐Long Wu, Chundong Gu, et al.. (2018). CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study. Annals of Oncology. 29. viii738–viii738. 7 indexed citations
10.
Lu, Chang, Jin‐Hyoung Kang, Hai‐Yan Tu, et al.. (2018). Co-occurring alterations in driver genes impact on EGFR-targeted therapy among patients with EGFR-mutant advanced non–small cell lung cancer. Annals of Oncology. 29. ix158–ix159. 1 indexed citations
11.
Zhou, C., You Lü, Thanyanan Reungwetwattana, et al.. (2018). Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC. Annals of Oncology. 29. viii740–viii740. 7 indexed citations
12.
13.
Han, Jiefei, Qiuyi Zhang, Qing Zhou, et al.. (2017). P3.02b-116 Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TKI. Journal of Thoracic Oncology. 12(1). S1263–S1264. 1 indexed citations
14.
Goto, Kōichi, Dong‐Wan Kim, Shun Lü, et al.. (2017). Phase II study of Crizotinib in East Asian patients (pts) with ROS1+ advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. ix91–ix91. 1 indexed citations
15.
Han, Jiefei, Qiuyi Zhang, Qing Zhou, et al.. (2017). JCES01.24 Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TKI. Journal of Thoracic Oncology. 12(1). S240–S241. 1 indexed citations
16.
Sun, Chongqi, Xin Cao, Jìng Guo, et al.. (2016). 59P Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening. Annals of Oncology. 27. ix17–ix17. 1 indexed citations
17.
Wang, Zhen, Yang-Si Li, Ning Zhao, et al.. (2015). Do-not-resuscitate orders among advanced-stage Chinese lung cancer patients who died in hospital. Supportive Care in Cancer. 24(4). 1763–1769. 9 indexed citations
18.
Yang, Lulu, Xu‐Chao Zhang, Shaokun Chuai, et al.. (2015). Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing. Journal of genetics and genomics. 42(10). 579–587. 2 indexed citations
19.
Chen, Hua‐Jun, Jin‐Ji Yang, Hong‐Hong Yan, et al.. (2013). Feasibility of computed tomography‐guided core needle biopsy in producing state‐of‐the‐art clinical management in Chinese lung cancer. Thoracic Cancer. 5(2). 155–161. 3 indexed citations
20.
An, Shejuan, Yi-Sheng Huang, Zhihong Chen, et al.. (2011). Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Medical Oncology. 29(2). 627–632. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karl Kölbeck Breakdown of academic impact, for papers by R. Lamy Breakdown of academic impact, for papers by H. Doubre Breakdown of academic impact, for papers by Rinat Galiulin Breakdown of academic impact, for papers by N. B. Leighl Breakdown of academic impact, for papers by William Berry Breakdown of academic impact, for papers by Ofer Rotem Breakdown of academic impact, for papers by Carina Hillenbach Breakdown of academic impact, for papers by C. Decroisette Breakdown of academic impact, for papers by Sook Jung Jo
Rankless by CCL
2026